RE: list of over 200 medicines in developnent for Thanks testy. That's a great resource for seeing what drugs are in development for treatment of various risk factors for heart disease. It is very encouraging to see Resverlogix as the only company with a BET inhibitor on that list (although there are other companies undergoing Phase I or early phase II iBET programs for non-heart disease ailments such as cancer). What is also encouraging is that other that RVX-208, it really seems like all of the other HDL-targeted therapies are either intravenous infusions (recombinant LCAT, recombinant apoAI/phospholipids) or have already been tried and failed to provide solid evidence of reduced heart disease (CETP inhibitors, niacin).
.
On a side note, the only family of drugs on that list that appear to act through are a novel mechanism for augmenting apoAI (as well as treating other aspect of dyslipidemia) are the PPARdelta agonists, of which is appears Metabolex's MBX-8025 has completed phase II (https://www.metabolex.com/MBX-8025.html). However, it was only an 8-week study and this drug is geared towards treating the multi-faceted complications of the metabolic syndrome, not so much targeting HDL.